The Cancer Research Data Commons (CRDC) presents its 2024 Fall Symposium:

#### Ten Years of Empowering Cancer Researchers

October 16 - October 17, 2024



### **CPTAC: Accelerating Cancer Research Through Multiomic Integration and Data Sharing**

Ratna Rajesh Thangudu, Ph.D.





**AL CANCER INSTITUTE** 

### Agenda

- CPTAC Historical Overview
- OCCPR's Leadership in Data Sharing
- Leveraging the CRDC
- Future of Data Access with PDC



- **CPTAC is** a national effort to accelerate the understanding of the molecular basis of cancer through large-scale proteome and genome analysis, known as proteogenomics.
- **Objective:** To systematically identify proteins that derive from alterations in cancer genomes and related biological processes, in order to understand the molecular basis of cancer that is not fully elucidated or not possible through genomics and to accelerate the translation of molecular findings into the clinic.



# **CPTAC**

- Collaborative effort by a multidisciplinary team
- Committed to open data sharing in proteomics
- Key Milestones:
  - **2006-2011**: Initial focus on standardizing proteomic technologies for cancer research.
  - **2012-2016**: Illumination of new tumor biology by focusing on TCGA tumor collection.
  - **2016-Now**: Advancing proteogenomics and translational research with prospective tumor collection.



### **Tumor Characterization Program**

**Cancertypes** 

Pancreas Cell 2021

Breast

Cell 2020

### CPTAC produces public resources of high-quality proteogenomic data of human tumors for hypothesis-driven science





Source: Dr Henry Rodriguez, OCCPR, NCI

# **Translational Research Program**



Phase 1b/2 trial: acute myeloid leukemia (BeatAML) (NCT01728402; Cell Rep Med 2024, PMID 38232702)



Breas



Ovarian

PMID 36001024)

**Refractory high grade serous** ovarian cancer (Cell 2023, PMID 37541199) [CT access to be submitted]

Breast Cancer Disc 2022 Phase 3 trial: neoadjuvant of paclitaxel-trastuzumab w/ or wo/ lapatinib in HER2+ breast cancer (NCT02547987 [Alliance/CALGB 40601]) manuscript submitted Phase 2 trial: neoadjuvant carboplatin and docetaxel in TNBC (CADENCE) (NCT02547987 & NCT02124902; Cancer Discovery 2022,

### **External Collaborations**

(expanding analytical expertise to trials outside the CPTAC network [pilot demonstration studies])

> Phase 1 trial: locoregional CAR T cells in glioma (NCT04185038; Cancer Discov 2023, PMID 36259971)

Phase 1/2 trial: ATR inhibitor in relapsed/refractory CLL (NCT03328273; Ther Adv Hematol 2023, PMID 37273420)

Phase 2 trial: pembrolizumab in lymphoma (NCT02243579; Front Oncol 2023, PMID 37205196)

Source: Dr Henry Rodriguez, OCCPR, NCI

Ž

2022

Oncogene 2021

# **Ongoing Programs**

### **Tumor Characterization**

- LUAD [CPTAC-Taiwan ICPC]
- AML
- GBM AYA
- Oligodendroglioma
- Sarcoma
- Melanoma
- Gastric
- LSCC
- Prostate
- Thyroid
- Liver
- LUAD onco negative

### **Translational/Clinical**

- Melanoma
- Multiple myeloma
- AML (Beat AML)
- NSCLC (ALCHEMIST)

### Collaborations







# **Championing Proteomic Data Sharing**

OCCPR has championed international data-sharing policies in proteomics since its inception.

#### Shaped by Key Data Sharing Policies:

- **Bermuda (1996)**: Early push for rapid data release in genomics.
- Fort Lauderdale (2003): Formalized immediate public access to data from large-scale projects.
- Amsterdam (2008): Established for proteomics, ensuring open data release without restrictions.
- **Sydney (2010)**: Emphasized open data sharing with additional considerations for clinical trials.

### **Impact on Cancer Research:**

OCCPR's adoption of these principles ensured timely public release of high-quality proteomic data, accelerating cancer research discoveries.



EBS

# Building the Foundation Data Sharing

**Early OCCPR Platforms:** Key resources developed to support open access of proteomic data.

**Collaboration with other NCI and NCBI resources:** To distribute imaging and genomic data.

**Open Science:** These resources embodied OCCPR's commitment to transparent, unrestricted data sharing, paving the way for PDC and CRDC.











# **CPTAC Comprehensive Molecular Data**

- Multi-Omics Analyses:
  - Genomics
  - Transcriptomics
  - Proteomics
  - Metabolomics
  - Lipidomics

### Protein Post-Translational Modifications (PTMs)

- Phosphoproteome
- Acetylome
- Glycoproteome
- Ubiquitylome



Ž

2023

Clinical Data: Patient demographics, diagnosis, treatment, exposure and follow-up data.

Histology & Radiology Images: Comprehensive imaging data for in-depth tissue and tumor analysis.

# Sharing Complex, High-Value Data: The Need for Specialized Resources

Why Specialized Resources Are Needed:

- Handling complex, large-scale multi-omics data.
- Ensuring **data standardization** and **harmonization** across studies.
- Providing access to cutting-edge analytical tools and computational infrastructure.
- Making data **FAIR** (Findable, Accessible, Interoperable, Reusable).
- Supporting the research community in reusing data to drive scientific breakthroughs.



Ž

EBS





# Leveraging the CRDC

### **Multiomic Data Resources:**

- Established Proteomic Data Commons for distributing mass spectrometry based proteomic data, operating as a node with in CRDC
- Migrated all of the historic data from CPTAC data portal
- Identified other nodes within CRDC for distribution of multiomics data types
- Genomic Data Commons for Genomic and Transcriptomic data
- Imaging Data Commons for pathology and radiology images

#### NCI Cancer Research Data Commons (CRDC)





### Serving as Knowledgebases

### • Adherence to FAIR Guidelines

- Common Data Models & Standardization
- Harmonization Pipelines
- Sophisticated Tools for Data Exploration
- Analysis tools for protein/gene expression clustering, building cohorts, and survival analysis.
- APIs for programmatic access



### Serving as Knowledgebases

- Adherence to FAIR Guidelines
- Common Data Models & Standardization
- Harmonization Pipelines
- Sophisticated Tools for Data Exploration
- Analysis tools for protein/gene expression clustering, building cohorts, and survival analysis.
- APIs for programmatic access

**TIONAL CANCER INSTITUTE** 



### Serving as Knowledgebases

- Adherence to FAIR Guidelines
- Common Data Models & Standardization
- Harmonization Pipelines
- Sophisticated Tools for Data Exploration
- Analysis tools for protein/gene expression clustering, building cohorts, and survival analysis.
- APIs for programmatic access



# **Supporting Computational Analysis**

- Simplifying access to complex multiomic data for analysis
  - Primary data analysis SB-CGC; FireCloud
  - Correlating the processed data ISB CGC
- Brings CPTAC data closer to the scalable compute infrastructure
- Versatile tools and analysis pipelines



# **Expanding CPTAC Data Sharing**

- Annual updates of the clinical data
- Cross-referencing across portals to ensure discoverability of multiomics data.
- Capture highly complex features of the cohorts
  - such as metastatic tumors of different cancer origin
  - bridging samples across different cohorts across international programs,
  - capturing multiple protocols used in studies, to name a few



AND

124 Cates 195 Aliquots		SUMMARY PDC Study Identifier PDC000221			
		Study ID 96296 Study Name CPTAC Experiment Type TMT11		fd1-89a4-11ea-b1fd-0aad30af8a83 C HNSCC Discovery Study - Proteom 1	
Description 😨		Protocol 🕑		Experimental Design 🚱	
otal records: 124					
Case Submitter ID	Genomic and Imaging Data Resource	Ethnicity *	Gender =	Race #	Morphology •
C3N-01946		not reported	male	white	8070/3
C3N-01754		not reported	maie	white	8070/3
C3L-01138		not reported	male	other	8070/3
C3N-03888	Courris Data Corverans	not reported	male	other	8070/3

PDC Cross referencing to GDC and TCIA



# **Expanding CPTAC Data Sharing**

• Expanded PDC to supporting CPTAC Metabolomic data Lipidomic Data

 Established a CPTAC Pan-Cancer resource on PDC to distribute data from the comprehensive data and papers





202

### **Expanding CPTAC Data Sharing**



https://aacrjournals.org/cancerres/issue/84/9

#### RESEARCH ARTICLE | SEPTEMBER 20 2024

NCI's Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data

Ratna R. Thangudu 🖬 🕲; Michael Holck 🕲; Deepak Singhal 🕹; Alexander Pilozzi 😓; Nathan Edwards 💩; Paul A. Rudnick 💩; Marcin J. Domagalski 💩; Padmini Chilappagari 🕲; Lei Ma 🕲; Yi Xin 😍; Toan Le 🕲; Kristen Nyce 🕲; Rekha Chaudhary 💩; Karen A. Ketchum 💿; Aaron Maurais @; Brian Connolly 🕲; Michael Riffle 🕲; Matthew C. Chambers 🎯; Brendan MacLean 🕲; Michael J. MacCoss 🕲; Peter B. McGarvey 🕲; Anand Basu 🕲; John Otridge 🕲; Esmeralda Casas-Silva 🕲; Sudha Venkatachari 🕲; Henry Rodriguez 🕿 🕲; Xu Zhang 🕿 🕲

Check for updates

+ Author & Article Information

Cancer Research Communications (2024) 4 (9): 2480-2488.

https://doi.org/10.1158/2767-9764.CRC-24-0243 Article history 🕑



https://doi.org/10.1158/2767-9764.CRC-24-0243



### **CPTAC Public Resources** (data, protocols, reagents)

#### P R O T E O M I C S . C A N C E R . G O V





CPTAC Program	https://proteomics.cancer.gov	cancer.proteomics@mail.nih.gov
Proteomic Data commons	https://pdc.cancer.gov	pdchelpdesk@mail.nih.gov
Genomic Data Commons	https://gdc.cancer.gov	support@nci-gdc.datacommons.io
Imaging Data Commons	https://portal.imaging.datacommons.cancer.gov	<pre>support@canceridc.dev</pre>
The Cancer Imaging Archive	https://www.cancerimagingarchive.net	help@cancerimagingarchive.net
Assay Portal	https://assays.cancer.gov/	cancer.proteomics@mail.nih.gov
Antibody Portal	https://antibodies.cancer.gov/	cancer.proteomics@mail.nih.gov

X 2 ~ 223

### Acknowledgements

NCI OCCPR Henry Rodriguez Xu Zhang Mehdi Mesri Ana Robles Eunkyung An Tara Hiltke Jasmin Bavarya

#### **CPTAC DCC** Karen Ketchum Yin Lu Shuang Cai

John Otridge

Sudha Venkatachari

Leidos

CRDC

Emi Casas-Silva CRDC Stakeholders CBIIT Leadership

#### PDC

Michael Holck Alexander Pilozzi Deepak Singhal Development Team

#### SME

Michael MacCoss Nathan Edwards Paul Rudnick

#### **CPTAC Consortium** Data Donors

Z 223